MarketPulse

patent settlement

5 articles
Investing.comInvesting.com··Jessica Mitacek

Hims & Hers Pivots to Brand-Name GLP-1s as Novo Deal Reshapes Growth Strategy

Hims & Hers reports Q1 earnings May 11 after settling patent dispute with Novo Nordisk, gaining rights to sell Wegovy and Ozempic while discontinuing compounded alternatives.
NVOHIMSGLP-1 drugsFDA regulations
GlobeNewswire Inc.GlobeNewswire Inc.··Catalyst Pharmaceuticals, Inc.

Catalyst Pharma Secures Patent Protection for FIRDAPSE Through 2035 Settlement

Catalyst Pharma settles patent litigation with Hetero Labs, blocking generic FIRDAPSE entry until 2035. Fourth major competitor settlement extends exclusivity.
CPRXrare diseasepatent settlement
BenzingaBenzinga··Vandana Singh

Pfizer Extends Vyndamax Patent Protection to 2031, Bolstering Post-Decade Revenue Outlook

Pfizer beats Q1 2026 expectations with $0.75 EPS and $14.45B in sales. Patent settlement extends Vyndamax protection to June 2031, ensuring revenue stability.
PFErevenue guidanceQ1 earnings
BenzingaBenzinga··Vandana Singh

Moderna Settles $950M Patent Dispute, Clears Path for Profitability Push

Moderna settles $950M patent dispute with Arbutus and Genevant, clearing legal uncertainty. Stock surges 8.85% as company targets 2028 breakeven with $4.5-5B cash by 2026.
MRNABNTXROIVABUSbalance sheet strengthmRNA technology
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Esperion Secures Fifth Settlement with Generic Drug Maker Over NEXLETOL, NEXLIZET Patents

Esperion secures fifth settlement with generic drugmaker Alkem, extending market exclusivity for cholesterol drugs NEXLETOL and NEXLIZET through April 2040.
SDZNYESPRpatent settlementgeneric drugs